SRR934894
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.593
- IL6_JAK_STAT3_SIGNALING+0.587
- TNFA_SIGNALING_VIA_NFKB+0.560
- INTERFERON_GAMMA_RESPONSE+0.539
- INFLAMMATORY_RESPONSE+0.509
- INTERFERON_ALPHA_RESPONSE+0.483
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.467
- COAGULATION+0.466
- ANGIOGENESIS+0.452
- HYPOXIA+0.396
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.369
- MITOTIC_SPINDLE-0.324
- WNT_BETA_CATENIN_SIGNALING-0.305
- PANCREAS_BETA_CELLS-0.278
- UV_RESPONSE_DN-0.236
- OXIDATIVE_PHOSPHORYLATION-0.216
- NOTCH_SIGNALING-0.176
- KRAS_SIGNALING_DN-0.145
- MYOGENESIS-0.139
- PROTEIN_SECRETION-0.075
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 647EE729-B34A-41F0-85AB-207F8C24420B | — | — | 0.896 |
| 2 | SRR934739 | — | — | 0.887 |
| 3 | SRR934872 | — | — | 0.883 |
| 4 | 70203945-80F8-4FA7-8C99-FEBAD3374103 | — | — | 0.881 |
| 5 | SRR934908 | — | — | 0.876 |
| 6 | SRR810571 | GTEX | — | 0.874 |
| 7 | 4B4647B5-1964-49A9-AC25-89AB4A669341 | — | — | 0.857 |
| 8 | SRR8613745 | — | A | 0.851 |
| 9 | SRR817658 | GTEX | — | 0.851 |
| 10 | AUR-AFUI-TTM1-A-1-0-R-A743-41 | — | C | 0.848 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.593 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.587 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.560 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.539 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.509 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.483 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.467 | Inavolisib | — uncovered |
| COAGULATION | 0.466 | Binimetinib | — uncovered |
| ANGIOGENESIS | 0.452 | Remibrutinib | — uncovered |
| HYPOXIA | 0.396 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.392 | Inavolisib | — uncovered |
| COMPLEMENT | 0.390 | Inavolisib | — uncovered |
| APOPTOSIS | 0.367 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.352 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.332 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.318 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.258 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.249 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.220 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.206 | Inavolisib | — uncovered |